Annual report · 2026 (year to date)

Long COVID: state of the evidence 2026

What the Open Source Medicine Foundation research tracker holds on Long COVID (PASC) for 1 January to 21 November 2026: literature flow, registered trials, agents under study, catalogued biomarkers and cohorts. Every figure is computed from the public JSON files linked at the end of this page.

  1. Research Tracker
  2. Annual Reports
  3. Long COVID: state of the evidence 2026
Contents:

Summary

74studies dated 2026 in the feed
345registered trials matched
109trials recruiting or active
33trials started in 2026
77biomarkers catalogued
7research cohorts indexed
Read this first. The literature feed is a rolling window of the 74 most recent PubMed results for this condition (currently spanning 5 November 2026 to 17 November 2026), not a complete census of 2026 publications. Monthly counts before the window opens are zero for that reason, not because nothing was published.

Literature indexed in 2026

The Long COVID feed holds 74 PubMed records with a 2026 publication date (74 unique PMIDs) out of 74 records in the feed, drawn from 63 distinct journals. This is a substantial sample.

Studies indexed per month, 20263774JanFebMarAprMayJunJulAugSepOctNov 2026: 7474NovDec
Records by publication month, 2026. Grey month labels are in the future. Months before the feed window opened are zero by construction.

Top journals

Top journals, 2026Frontiers in immunologyFrontiers in immunology: 44Open forum infectious diseasesOpen forum infectious diseases: 22Journal of clinical medicineJournal of clinical medicine: 22International journal of mole…International journal of molecular sciences: 22JMIR formative researchJMIR formative research: 22Journal of virologyJournal of virology: 22Frontiers in health servicesFrontiers in health services: 22BMC public healthBMC public health: 22Ciencia & saude coletivaCiencia & saude coletiva: 22Journal of pediatric gastroen…Journal of pediatric gastroenterology and nutrition: 11
Journals with the most 2026 records in the feed (top 10; ties broken by first appearance).

Browse the live feed: Long COVID research tracker. Weekly changes are in the research digest.

Clinical trials

345 of the 635 ClinicalTrials.gov records in the tracker snapshot (taken 2026-11-21) match Long COVID (345 via the tracker's curated condition mapping). 109 are recruiting, not yet recruiting, enrolling by invitation or active; 33 list a 2026 start date and 139 had their registry record updated in 2026. Median planned or actual enrollment is 60 participants (345 trials report a figure).

By status

Trials by statusCompletedCompleted: 152152UnknownUnknown: 5757RecruitingRecruiting: 5555Not Yet RecruitingNot Yet Recruiting: 2626Active Not RecruitingActive Not Recruiting: 2525WithdrawnWithdrawn: 1414TerminatedTerminated: 1010Enrolling By Invitati…Enrolling By Invitation: 33SuspendedSuspended: 33
Overall status as recorded on ClinicalTrials.gov at snapshot.

By phase

Trials by phaseNot applicableNot applicable: 219219Phase 2Phase 2: 7777Phase 3Phase 3: 2222Phase 1Phase 1: 1414Phase 4Phase 4: 77Early phase 1Early phase 1: 66
"Not applicable" covers behavioural, device, rehabilitation and observational designs.

By sponsor type

Trials by sponsor typeAcademic / otherAcademic / other: 289289IndustryIndustry: 3939US federal (non-NIH)US federal (non-NIH): 77Other governmentOther government: 66NIHNIH: 33Research networkResearch network: 11
Lead-sponsor class from the registry; "Academic / other" is the registry's OTHER category.

Agents under investigation

Top agents by trial countPaxlovid (Nirmatrelvi…Paxlovid (Nirmatrelvir/Ritonavir): 88AcupunctureAcupuncture: 66Hyperbaric Oxygen The…Hyperbaric Oxygen Therapy (HBOT): 44Transcranial Direct C…Transcranial Direct Current Stimulation: 33FluvoxamineFluvoxamine: 33MetforminMetformin: 33RitonavirRitonavir: 33ExerciseExercise: 33NaltrexoneNaltrexone: 22Structured PacingStructured Pacing: 22
Interventions named in the most matched trials (top 10 of 428 distinct agents). A trial testing several agents counts once per agent.
AgentTrialsOf which active
Paxlovid (Nirmatrelvir/Ritonavir)83
Acupuncture63
Hyperbaric Oxygen Therapy (HBOT)41
Transcranial Direct Current Stimulation31
Fluvoxamine31
Metformin30
Ritonavir30
Exercise31
Naltrexone21
Structured Pacing20

Trials starting in 2026

NCTTrialStatusPhaseStartSponsor
NCT07682402Taurine Supplementation in Adolescents With Post-COVID Condition
Taurine
Not Yet RecruitingPhase 12026-12-30University of Alberta
NCT07947901Block-LC SGB Treatment Trial
Bupivacaine-Hcl, Lidocaine
Not Yet RecruitingPhase 22026-12-09National Institute of Allergy and Infectious Diseases (NIAID)
NCT06907251Dapagliflozin for Long COVID Syndrome
Dapagliflozin
Not Yet RecruitingPhase 32026-12-01Ottawa Heart Institute Research Corporation
NCT07724834CD19-B Cell Depletion in PAIS-ME/CFS Patients
Inebilizumab
Not Yet RecruitingPhase 22026-12-01Charite University, Berlin, Germany
NCT07388550Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Keytruda
Not Yet RecruitingPhase 12026-11-25National Institute of Neurological Disorders and Stroke (NINDS)
NCT07916259The Study of Brave-LC LDN Treatment Trial
Naltrexone
Not Yet RecruitingPhase 32026-11-16National Institute of Allergy and Infectious Diseases (NIAID)
NCT07930637Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome
Rimonabant
Not Yet RecruitingPhase 22026-11-06Sinfatin S.L
NCT07697261Fatigue in Long COVID
Lightning Process, Activity Pacing
Not Yet RecruitingNot applicable2026-11McMaster University

Showing the 8 most recent of 33 trials with a 2026 start date.

All tracked trials: clinical trials tracker.

Therapeutic agents catalogue

The OSMF therapeutic-agents catalogue lists 437 agents with Long COVID as a primary condition (of 609 agents overall). Evidence level is the catalogue's own coarse grading, assigned automatically from the number and type of linked studies and trials; it is not a GRADE assessment.

Agents by evidence levelPreliminaryPreliminary: 381381ModerateModerate: 4141AnecdotalAnecdotal: 1515
Catalogue evidence grading: anecdotal, preliminary or moderate. No agent for any condition is graded higher than moderate.

Browse: therapeutics atlas and agents.

Biomarkers catalogued

The Long COVID biomarker atlas (last edited 2026-06-29) holds 77 marker entries across 10 categories, citing 8 distinct DOIs: 50 reported elevated, 14 reduced and 13 with mixed or inconsistent findings. Direction is relative to the comparison group in the cited source (usually healthy controls) and a single entry can rest on one study.

Biomarkers by category and directionMetabolicMetabolic - up: 11Metabolic - down: 10Metabolic - mixed: 223InflammatoryInflammatory - up: 11Inflammatory - down: 1Inflammatory - mixed: 214VascularVascular - up: 88ImmuneImmune - up: 6Immune - mixed: 17CoagulationCoagulation - up: 66ProteomicProteomic - up: 3Proteomic - mixed: 25LipidomicLipidomic - down: 1Lipidomic - mixed: 34NeurologicalNeurological - up: 44MicrobiomeMicrobiome - up: 1Microbiome - down: 2Microbiome - mixed: 14ViralViral - mixed: 22
ElevatedReducedMixed / inconsistentNot stated
Marker entries by atlas category, split by reported direction of change.
CategoryElevatedReducedMixedTotal
Metabolic1110223
Inflammatory111214
Vascular8008
Immune6017
Coagulation6006
Proteomic3025
Lipidomic0134
Neurological4004
Microbiome1214
Viral0022

Full atlas: Long COVID biomarker atlas.

Research cohorts

7 of the 32 cohorts in the OSMF post-acute infection syndrome (PAIS) cohort database relate to Long COVID, together enrolling about 29,623 participants where a figure is recorded. This is a curated database, not a systematic census of cohorts.

CohortDesignEnrolledBiobankRegistration
NIH RECOVER-Adult Cohortprospective non inception15,000activeNCT05172024
Long COVID Host Genetics Initiative GWASregistry linkage6,450active—
Patient-Led Long COVID international cohort (Davis 2021)survey3,762not applicable—
PHOSP-COVID (UK post-hospitalisation COVID-19)prospective non inception2,320activeISRCTN10980107
Jinyintan (Wuhan) COVID-19 discharge cohort (Huang)prospective non inception1,733unknown—
Bergen COVID-19 home-isolated cohort (Blomberg)prospective inception312active—
Amsterdam Long COVID muscle-biopsy PEM cohort (Appelman)case control46unknownNCT05225688

Methods

This page was generated by scripts/build_reports.py on 21 November 2026 from the data snapshot described below. No number is entered by hand.

Limitations

Download the data

All inputs are public JSON files in the research-tracker repository, licensed for reuse with attribution.

Suggested citation

Open Source Medicine Foundation. Long COVID: state of the evidence 2026 (year-to-date, generated 21 November 2026). Open Source Medicine Foundation; 2026. https://research.opensourcemed.info/reports/long-covid-state-of-the-evidence-2026.html

For a stable reference, cite the generation date shown; the page is regenerated as data arrive. Weekly updates: subscribe on Substack or follow the digest RSS feed.

Disclaimer. This report is an automated description of a research database maintained by the Open Source Medicine Foundation. It is not a systematic review and not medical advice. Discuss any treatment decision with a qualified clinician.